Meeting of the Chronic Fatigue Syndrome Advisory Committee, 21300 [2018-09844]

Download as PDF 21300 Federal Register / Vol. 83, No. 90 / Wednesday, May 9, 2018 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Chronic Fatigue Syndrome Advisory Committee Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services (HHS) is hereby giving notice that a webinar meeting of the Chronic Fatigue Syndrome Advisory Committee (CFSAC) will take place and open to the public to listen in via a toll free number. DATES: The CFSAC webinar will be held on Wednesday, June 20, 2018, from 9:00 a.m. until 5:00 p.m. and on Thursday, June 21, 2018 from 9:00 a.m. to 5:00 p.m. (EST). ADDRESSES: This meeting will be broadcasted to the public as a webinar. A webinar is a virtual meeting. Registration is not required for the webinar. SUMMARY: amozie on DSK3GDR082PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Gustavo Ceinos, MPH, Designated Federal Officer, Chronic Fatigue Syndrome Advisory Committee, Department of Health and Human Services, 200 Independence Avenue SW, Room 728F.6, Washington, DC 20201. Please direct all inquiries to cfsac@hhs.gov. SUPPLEMENTARY INFORMATION: The CFSAC is authorized in 42 U.S.C.217a, Section 222 of the Public Health Service Act, as amended. The purpose of the CFSAC is to provide advice and recommendations to the Secretary of Health and Human Services (HHS), through the Assistant Secretary for Health (ASH), on issues related to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The issues can include factors affecting access and care for persons with ME/CFS; the science and definition of ME/CFS; and broader public health, clinical, research, and educational issues related to ME/ CFS. The agenda for this meeting, call-in information and location will be posted on the CFSAC website https:// www.hhs.gov/ash/advisory-committees/ cfsac/meetings/. A one hour of public comments via telephone will be scheduled for the first and second day of the webinar. Individuals will have five minutes to present their comments. Priority will be given to individuals who have not provided public comments within the VerDate Sep<11>2014 17:39 May 08, 2018 Jkt 244001 previous year. We are unable to place international calls for public comments. To request a time slot for public comments, please send an email to cfsac@hhs.gov by Wednesday, June 13, 2018. The email should contain the speaker’s name and the telephone number that will be used for public comments. Individuals who would like to provide written testimony to Committee members should submit a copy of their testimony prior to the meeting. It is preferred, but not required, that the submitted testimony be prepared in digital format and typed using a 12pitch font. Copies of the written testimony must not exceed 5 singlespace pages, and it is preferred, but not required that the document be prepared in the MS Word format. Please note that PDF files, handwritten notes, charts, and photographs cannot be accepted. Materials submitted should not include sensitive personal information, such as social security number, birthdates, driver’s license number, passport number, financial account number, or a credit or debit card number. If you wish to remain anonymous, you must specify this in the document. The Committee welcomes input on any topic related to ME/CFS. Dated: April 27, 2018. Gustavo Ceinos, Commander, USPHS, Designated Federal Officer. [FR Doc. 2018–09844 Filed 5–8–18; 8:45 am] BILLING CODE 4150–42–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Identification of Biomarkers of HIV–1 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 Pathogenesis and Substance Abuse Comorbidity (R01–Clinical Trials Not Allowed). Date: June 6, 2018. Time: 12:00 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301–827–5820, hiromi.ono@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Improving Implementation of Seek, Test, Treat & Retain Strategies Among People Who Inject Drugs in Low to Middle Income Countries (R01–Clinical Trial Required). Date: June 14, 2018. Time: 12:00 p.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center. 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute onDrug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301–827–5820, hiromi.ono@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Identification of Genetic and Genomic Variants byNext-Gen Sequencing in NonHuman Animal Models (U01). Date: June 21, 2018. Time: 12:00 p.m. to 2:00 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, NationalInstitute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301– 827–5819, gm145A@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: May 4, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–09900 Filed 5–8–18; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\09MYN1.SGM 09MYN1

Agencies

[Federal Register Volume 83, Number 90 (Wednesday, May 9, 2018)]
[Notices]
[Page 21300]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09844]



[[Page 21300]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Chronic Fatigue Syndrome Advisory Committee

AGENCY: Department of Health and Human Services, Office of the 
Secretary, Office of the Assistant Secretary for Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S. 
Department of Health and Human Services (HHS) is hereby giving notice 
that a webinar meeting of the Chronic Fatigue Syndrome Advisory 
Committee (CFSAC) will take place and open to the public to listen in 
via a toll free number.

DATES: The CFSAC webinar will be held on Wednesday, June 20, 2018, from 
9:00 a.m. until 5:00 p.m. and on Thursday, June 21, 2018 from 9:00 a.m. 
to 5:00 p.m. (EST).

ADDRESSES: This meeting will be broadcasted to the public as a webinar. 
A webinar is a virtual meeting. Registration is not required for the 
webinar.

FOR FURTHER INFORMATION CONTACT: Gustavo Ceinos, MPH, Designated 
Federal Officer, Chronic Fatigue Syndrome Advisory Committee, 
Department of Health and Human Services, 200 Independence Avenue SW, 
Room 728F.6, Washington, DC 20201. Please direct all inquiries to 
[email protected].

SUPPLEMENTARY INFORMATION: The CFSAC is authorized in 42 U.S.C.217a, 
Section 222 of the Public Health Service Act, as amended. The purpose 
of the CFSAC is to provide advice and recommendations to the Secretary 
of Health and Human Services (HHS), through the Assistant Secretary for 
Health (ASH), on issues related to myalgic encephalomyelitis/chronic 
fatigue syndrome (ME/CFS). The issues can include factors affecting 
access and care for persons with ME/CFS; the science and definition of 
ME/CFS; and broader public health, clinical, research, and educational 
issues related to ME/CFS.
    The agenda for this meeting, call-in information and location will 
be posted on the CFSAC website https://www.hhs.gov/ash/advisory-committees/cfsac/meetings/.
    A one hour of public comments via telephone will be scheduled for 
the first and second day of the webinar. Individuals will have five 
minutes to present their comments. Priority will be given to 
individuals who have not provided public comments within the previous 
year. We are unable to place international calls for public comments. 
To request a time slot for public comments, please send an email to 
[email protected] by Wednesday, June 13, 2018. The email should contain the 
speaker's name and the telephone number that will be used for public 
comments.
    Individuals who would like to provide written testimony to 
Committee members should submit a copy of their testimony prior to the 
meeting. It is preferred, but not required, that the submitted 
testimony be prepared in digital format and typed using a 12-pitch 
font. Copies of the written testimony must not exceed 5 single-space 
pages, and it is preferred, but not required that the document be 
prepared in the MS Word format. Please note that PDF files, handwritten 
notes, charts, and photographs cannot be accepted. Materials submitted 
should not include sensitive personal information, such as social 
security number, birthdates, driver's license number, passport number, 
financial account number, or a credit or debit card number. If you wish 
to remain anonymous, you must specify this in the document.
    The Committee welcomes input on any topic related to ME/CFS.

    Dated: April 27, 2018.
Gustavo Ceinos,
Commander, USPHS, Designated Federal Officer.
[FR Doc. 2018-09844 Filed 5-8-18; 8:45 am]
 BILLING CODE 4150-42-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.